Abstract

Deferasirox Compared With Deferoxamine For The Removal Of Cardiac Iron In Patients With β-Thalassemia Major: 2-Year Data From The Cordelia Extension

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)
Yesim Aydinok ... John B Porter
Blood | VOL. 122
Yesim Aydinok, et. al.Yesim Aydinok ... John B Porter
15 Nov 2013
A Multicenter, Randomized, Open-Label Trial Evaluating Deferasirox Compared with Deferoxamine for the Removal of Cardiac Iron in Patients with β-Thalassemia Major and Iron Overload (CORDELIA).
Dudley J Pennell ... Yesim Aydinok
Blood | VOL. 120
Dudley J Pennell, et. al.Dudley J Pennell ... Yesim Aydinok
16 Nov 2012
Chelation Choices and Iron Burden Among Patients with Thalassemia in the 21st Century: a Report From the Thalassemia Clinical Research Network (TCRN) Longitudinal Cohort.
Janet L Kwiatkowski ... Ellis J Neufeld
Blood | VOL. 114
Janet L Kwiatkowski, et. al.Janet L Kwiatkowski ... Ellis J Neufeld
20 Nov 2009
Continued Improvement and Normalization of Myocardial T2* In Patients with β-thalassemia Major Treated with Deferasirox (Exjade®) for up to 3 Years
Dudley Pennell ... Ali Taher
Blood | VOL. 116
Dudley Pennell, et. al.Dudley Pennell ... Ali Taher
19 Nov 2010
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis.
Ayalew Tefferi ... Tiziano Barbui
Blood | VOL. -
Ayalew Tefferi, et. al.Ayalew Tefferi ... Tiziano Barbui
08 Aug 2024
CDK9 phosphorylates RUNX1 to promote megakaryocytic fate in megakaryocytic-erythroid progenitors.
Nayoung Kwon ... Diane S Krause
Blood | VOL. -
Nayoung Kwon, et. al.Nayoung Kwon ... Diane S Krause
05 Aug 2024
Asciminib Monotherapy as Frontline Treatment of Chronic Phase Chronic Myeloid Leukaemia – Results from the ASCEND Study
David T Yeung ... Timothy P Hughes
Blood | VOL. -
David T Yeung, et. al.David T Yeung ... Timothy P Hughes
05 Aug 2024
Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS.
Esteban Arrieta-Bolaños ... Katharina Fleischhauer
Blood | VOL. -
Esteban Arrieta-Bolaños, et. al.Esteban Arrieta-Bolaños ... Katharina Fleischhauer
05 Aug 2024
View more papers